Starling Oncology
STLN
Starling Oncology (STLN) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.08
- EPS estimate
- −$0.06
- EPS surprise
- −25.00%
- Revenue surprise
- +3.87%
- Revenue
- $161.3M
- Revenue estimate
- $155.3M
- Reported
- Aug 6, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | −$0.06 | −$0.08 | −25.00% | $161.3M | SEC |
| Q1 2026 | May 7, 2026 | −$0.09 | −$0.02 | +77.14% | $147.4M | SEC |
| Q4 2025 | Mar 12, 2026 | −$0.09 | −$0.06 | +33.33% | $142.0M | SEC |
| Q3 2025 | Nov 13, 2025 | −$0.11 | −$0.14 | −23.57% | $136.6M | SEC |
| Q2 2025 | Aug 13, 2025 | −$0.12 | −$0.15 | −25.00% | $119.8M | SEC |
| Q1 2025 | May 14, 2025 | $0.00 | −$0.21 | +0.00% | $104.4M | SEC |
| Q4 2024 | Mar 24, 2025 | −$0.08 | −$0.14 | −75.00% | $100.3M | SEC |
| Q3 2024 | Nov 13, 2024 | −$0.07 | −$0.18 | −157.14% | $99.9M | SEC |
| Q2 2024 | Aug 13, 2024 | −$0.09 | −$0.17 | −88.89% | $98.6M | SEC |
| Q1 2024 | May 14, 2024 | −$0.12 | −$0.22 | −83.33% | $95.0M | SEC |
| Q4 2023 | Mar 27, 2024 | −$0.11 | −$0.21 | −90.91% | $86.0M | SEC |
| Q3 2023 | Nov 8, 2023 | −$0.13 | −$0.19 | −46.15% | $82.0M | SEC |
| Q2 2023 | Aug 9, 2023 | −$0.17 | −$0.19 | −11.76% | $80.2M | SEC |
| Q1 2023 | May 10, 2023 | −$0.17 | −$0.33 | −94.12% | $76.2M | SEC |
| Q4 2022 | Mar 9, 2023 | −$0.20 | −$0.16 | +20.00% | $71.4M | SEC |
| Q3 2022 | Nov 9, 2022 | −$0.18 | −$0.17 | +5.56% | $65.0M | SEC |
| Q2 2022 | Aug 9, 2022 | $0.00 | −$0.09 | +0.00% | $61.0M | SEC |
| Q4 2021 | Mar 10, 2022 | $0.00 | −$0.15 | +0.00% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Starling Oncology (STLN) last report earnings?
Starling Oncology last reported on Aug 6, 2026, covering fiscal Q2 2026.
Did STLN beat earnings estimates?
No. Starling Oncology reported EPS of −$0.08 for Q2 2026 against a −$0.06 estimate — a 25.00% miss.
How much revenue did STLN report last quarter?
Starling Oncology reported $161.3M in revenue for Q2 2026, against a consensus estimate of $155.3M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.